Patients with triple negative breast cancer: Is there an optimal adjuvant treatment?

被引：9

作者：

Burstein, Harold J. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

BREAST | 2013年 / 22卷

关键词：

RANDOMIZED-TRIALS; DOCETAXEL; CYCLOPHOSPHAMIDE; PACLITAXEL; SURVIVAL; SUBTYPES; WOMEN; HER2;

D O I：

10.1016/j.breast.2013.07.027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：S147 / S148

页数：2

共 13 条

[1] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[2] Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy [J].

Byrski, Tomasz ;

Gronwald, Jacek ;

Huzarski, Tomasz ;

Grzybowska, Ewa ;

Budryk, Magdalena ;

Stawicka, Malgorzata ;

Mierzwa, Tomasz ;

Szwiec, Marek ;

Wisniowski, Rafal ;

Siolek, Monika ;

Dent, Rebecca ;

Lubinski, Jan ;

Narod, Steven .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :375-379

[3]

Cameron D, 2012, SAN ANT BREAST CANC

[4] Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial [J].

Cheang, Maggie C. U. ;

Voduc, K. David ;

Tu, Dongsheng ;

Jiang, Shan ;

Leung, Samuel ;

Chia, Stephen K. ;

Shepherd, Lois E. ;

Levine, Mark N. ;

Pritchard, Kathleen I. ;

Davies, Sherri ;

Stijleman, Inge J. ;

Davis, Carole ;

Ebbert, Mark T. W. ;

Parker, Joel S. ;

Ellis, Matthew J. ;

Bernard, Philip S. ;

Perou, Charles M. ;

Nielsen, Torsten O. .

CLINICAL CANCER RESEARCH, 2012, 18 (08) :2402-2412

[5] Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer [J].

Curigliano, Giuseppe ;

Viale, Giuseppe ;

Bagnardi, Vincenzo ;

Fumagalli, Luca ;

Locatelli, Marzia ;

Rotmensz, Nicole ;

Ghisini, Raffaella ;

Colleoni, Marco ;

Munzone, Elisabetta ;

Veronesi, Paolo ;

Zurrida, Stefano ;

Nole, Franco ;

Goldhirsch, Aron .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5693-5699

[6] HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials [J].

Gennari, Alessandra ;

Sormani, Maria Pia ;

Pronzato, Paolo ;

Puntoni, Matteo ;

Colozza, Mariantonietta ;

Pfeffer, Ulrich ;

Bruzzi, Paolo .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01) :14-20

[7] HER2 and response to paclitaxel in node-positive breast cancer [J].

Hayes, Daniel F. ;

Thor, Ann D. ;

Dressler, Lynn G. ;

Weaver, Donald ;

Edgerton, Susan ;

Cowan, David ;

Broadwater, Gloria ;

Goldstein, Lori J. ;

Martino, Silvana ;

Ingle, James N. ;

Henderson, I. Craig ;

Norton, Larry ;

Winer, Eric P. ;

Hudis, Clifford A. ;

Ellis, Matthew J. ;

Berry, Donald A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (15) :1496-1506

[8] Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial [J].

Hugh, Judith ;

Hanson, John ;

Cheang, Maggie Chon U. ;

Nielsen, Torsten O. ;

Perou, Charles M. ;

Dumontet, Charles ;

Reed, John ;

Krajewska, Maryla ;

Treilleux, Isabelle ;

Rupin, Matthieu ;

Magherini, Emmanuelle ;

Mackey, John ;

Martin, Miguel ;

Vogel, Charles .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1168-1176

[9] Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial [J].

Joensuu, Heikki ;

Kellokumpu-Lehtinen, Pirkko-Liisa ;

Huovinen, Riikka ;

Jukkola-Vuorinen, Arja ;

Tanner, Minna ;

Kokko, Riitta ;

Ahlgren, Johan ;

Auvinen, Paivi ;

Paija, Outi ;

Helle, Leena ;

Villman, Kenneth ;

Nyandoto, Paul ;

Nilsson, Greger ;

Pajunen, Marjo ;

Asola, Raija ;

Poikonen, Paula ;

Leinonen, Mika ;

Kataja, Vesa ;

Bono, Petri ;

Lindman, Henrik .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (01) :11-18

[10] Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735 [J].

Jones, Stephen ;

Holmes, Frankie Ann ;

O'Shaughnessy, Joyce ;

Blum, Joanne L. ;

Vukelja, Svetislava J. ;

McIntyre, Kristi J. ;

Pippen, John E. ;

Bordelon, James H. ;

Kirby, Robert L. ;

Sandbach, John ;

Hyman, William J. ;

Richards, Donald A. ;

Mennel, Robert G. ;

Boehm, Kristi A. ;

Meyer, Wally G. ;

Asmar, Lina ;

Mackey, Daniel ;

Riedel, Stefan ;

Muss, Hyman ;

Savin, Michael A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1177-1183

← 1 2 →